{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T22:24:38Z","timestamp":1785795878209,"version":"3.56.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,9,16]]},"DOI":"10.7759\/cureus.18032","type":"journal-article","created":{"date-parts":[[2021,9,17]],"date-time":"2021-09-17T03:35:43Z","timestamp":1631849743000},"source":"Crossref","is-referenced-by-count":15,"title":["A Review of Eptinezumab Use in Migraine"],"prefix":"10.7759","author":[{"given":"Abhigyan","family":"Datta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shashi","family":"Maryala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417738202","article-title":"Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition","volume":"38","year":"2018","unstructured":"Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018, 38.1-211. 10.1177\/0333102417738202","journal-title":"Cephalalgia"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01208-0","article-title":"Migraine remains second among the world's causes of disability, and first among young women: findings from GBD2019","volume":"21","author":"Steiner TJ","year":"2020","unstructured":"Steiner TJ, Stovner LJ, Jensen R, Uluduz D, Katsarava Z. Migraine remains second among the world's causes of disability, and first among young women: findings from GBD2019. J Headache Pain. 2020, 21:137. 10.1186\/s10194-020-01208-0","journal-title":"J Headache Pain"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s11940-017-0463-4","article-title":"Anti-CGRP Monoclonal antibodies: the next era of migraine prevention?","volume":"19","author":"Tso AR","year":"2017","unstructured":"Tso AR, Goadsby PJ. Anti-CGRP Monoclonal antibodies: the next era of migraine prevention?. Curr Treat Options Neurol. 2017, 19:27. 10.1007\/s11940-017-0463-4","journal-title":"Curr Treat Options Neurol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-018-3547-3","article-title":"The efficacy and safety of calcitonin gene-related peptide monoclonal antibody for episodic migraine: a meta-analysis","volume":"39","author":"Zhu Y","year":"2018","unstructured":"Zhu Y, Liu Y, Zhao J, Han Q, Liu L, Shen X. The efficacy and safety of calcitonin gene-related peptide monoclonal antibody for episodic migraine: a meta-analysis. Neurol Sci. 2018, 39:2097-106. 10.1007\/s10072-018-3547-3","journal-title":"Neurol Sci"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/s0165-1838(98)00033-2","article-title":"Calcitonin gene-related peptide and nitric oxide in the trigeminal ganglion: cerebral vasodilatation from trigeminal nerve stimulation involves mainly calcitonin gene-related peptide","volume":"70","author":"Edvinsson L","year":"1998","unstructured":"Edvinsson L, Mulder H, Goadsby PJ, Uddman R. Calcitonin gene-related peptide and nitric oxide in the trigeminal ganglion: cerebral vasodilatation from trigeminal nerve stimulation involves mainly calcitonin gene-related peptide. J Auton Nerv Syst. 1998, 70:15-22. 10.1016\/s0165-1838(98)00033-2","journal-title":"J Auton Nerv Syst"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-019-03769-8","article-title":"CGRP and headache: a brief review","volume":"40","author":"Tepper SJ","year":"2019","unstructured":"Tepper SJ. CGRP and headache: a brief review. Neurol Sci. 2019, 40:99-105. 10.1007\/s10072-019-03769-8","journal-title":"Neurol Sci"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1177\/0333102410368444","article-title":"Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura","volume":"30","author":"Hansen JM","year":"2010","unstructured":"Hansen JM, Hauge AW, Olesen J, Ashina M. Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura. Cephalalgia. 2010, 30:1179-86. 10.1177\/0333102410368444","journal-title":"Cephalalgia"},{"key":"ref8","unstructured":"Vyepti Prescribing Information. (2020). Accessed. August 28, 2021: https:\/\/www.lundbeck.com\/content\/dam\/lundbeck-com\/americas\/united-states\/products\/neurology\/vyepti_pi_us_en.pdf."},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01300-4","article-title":"Eptinezumab: first approval","volume":"80","author":"Dhillon S","year":"2020","unstructured":"Dhillon S. Eptinezumab: first approval. Drugs. 2020, 80:733-9. 10.1007\/s40265-020-01300-4","journal-title":"Drugs"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2019.1635452","article-title":"Fremanezumab for the preventive treatment of migraine in adults","volume":"12","author":"Lionetto L","year":"2019","unstructured":"Lionetto L, Curto M, Cisale GY, Capi M, Cipolla F, Guglielmetti M, Martelletti P. Fremanezumab for the preventive treatment of migraine in adults. Expert Rev Clin Pharmacol. 2019, 12:741-8. 10.1080\/17512433.2019.1635452","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-1002-7","article-title":"Galcanezumab: first global approval","volume":"78","author":"Lamb YN","year":"2018","unstructured":"Lamb YN. Galcanezumab: first global approval. Drugs. 2018, 78:1769-75. 10.1007\/s40265-018-1002-7","journal-title":"Drugs"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0944-0","article-title":"Erenumab: first global approval","volume":"78","author":"Markham A","year":"2018","unstructured":"Markham A. Erenumab: first global approval. Drugs. 2018, 78:1157-61. 10.1007\/s40265-018-0944-0","journal-title":"Drugs"},{"key":"ref13","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.88.16_supplement.P2.155","article-title":"Rational design of a monoclonal antibody (mAb) inhibiting calcitonin gene-related peptide (CGRP), ALD403, intended for the prevention of migraine","volume":"88","author":"Baker B","year":"2017","unstructured":"Baker B, Schaeffler B, Cady R, Latham J, Whitaker T, Smith JT . Rational design of a monoclonal antibody (mAb) inhibiting calcitonin gene-related peptide (CGRP), ALD403, intended for the prevention of migraine. Neurology. 2017, 88:","journal-title":"Neurology"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.567","article-title":"Population pharmacokinetic and exposure-response analysis of eptinezumab in the treatment of episodic and chronic migraine","volume":"8","author":"Baker B","year":"2020","unstructured":"Baker B, Schaeffler B, Beliveau M, et al.. Population pharmacokinetic and exposure-response analysis of eptinezumab in the treatment of episodic and chronic migraine. Pharmacol Res Perspect. 2020, 8:e00567. 10.1002\/prp2.567","journal-title":"Pharmacol Res Perspect"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(14)70209-1","article-title":"Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial","volume":"13","author":"Dodick DW","year":"2014","unstructured":"Dodick DW, Goadsby PJ, Silberstein SD, et al.. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol. 2014, 13:1100-7. 10.1016\/S1474-4422(14)70209-1","journal-title":"Lancet Neurol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1177\/0333102419858355","article-title":"Eptinezumab for prevention of chronic migraine: a randomized phase 2b clinical trial","volume":"39","author":"Dodick DW","year":"2019","unstructured":"Dodick DW, Lipton RB, Silberstein S, et al.. Eptinezumab for prevention of chronic migraine: a randomized phase 2b clinical trial. Cephalalgia. 2019, 39:1075-85. 10.1177\/0333102419858355","journal-title":"Cephalalgia"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1177\/0333102420905132","article-title":"Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1)","volume":"40","author":"Ashina M","year":"2020","unstructured":"Ashina M, Saper J, Cady R, et al.. Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia. 2020, 40:241-54. 10.1177\/0333102420905132","journal-title":"Cephalalgia"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2020.11.007","article-title":"Eptinezumab for the prevention of episodic migraine: sustained effect through 1\u00a0year of treatment in the PROMISE-1 study","volume":"42","author":"Smith TR","year":"2020","unstructured":"Smith TR, Janelidze M, Chakhava G, et al.. Eptinezumab for the prevention of episodic migraine: sustained effect through 1\u00a0year of treatment in the PROMISE-1 study. Clin Ther. 2020, 42:2254-65.e3. 10.1016\/j.clinthera.2020.11.007","journal-title":"Clin Ther"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000009169","article-title":"Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2","volume":"94","author":"Lipton RB","year":"2020","unstructured":"Lipton RB, Goadsby PJ, Smith J, et al.. Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology. 2020, 94:e1365-77. 10.1212\/WNL.0000000000009169","journal-title":"Neurology"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01186-3","article-title":"Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24\u2009weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy-2) study","volume":"21","author":"Silberstein S","year":"2020","unstructured":"Silberstein S, Diamond M, Hindiyeh NA, et al.. Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24\u2009weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy-2) study. J Headache Pain. 2020, 21:120. 10.1186\/s10194-020-01186-3","journal-title":"J Headache Pain"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/head.14120","article-title":"Patient-identified most bothersome symptom in preventive migraine treatment with eptinezumab: a novel patient-centered outcome","volume":"61","author":"Lipton RB","year":"2021","unstructured":"Lipton RB, Dodick DW, Ailani J, McGill L, Hirman J, Cady R. Patient-identified most bothersome symptom in preventive migraine treatment with eptinezumab: a novel patient-centered outcome. Headache. 2021, 61:766-76. 10.1111\/head.14120","journal-title":"Headache"},{"key":"ref22","article-title":"Treatment with eptinezumab demonstrated meaningful improvements in patients with chronic migraine experiencing a high frequency of severe migraines","volume":"59","author":"Nagy AJ","year":"2019","unstructured":"Nagy AJ, Silberstein SD, Cady R, Kassel E, Hirman J, Smith J. Treatment with eptinezumab demonstrated meaningful improvements in patients with chronic migraine experiencing a high frequency of severe migraines. Headache. 2019, 59:163.","journal-title":"Headache"},{"key":"ref23","doi-asserted-by":"crossref","DOI":"10.1016\/j.jval.2019.04.1355","article-title":"Impact of eptinezumab on the health-related quality of life (HRQoL) of patients with episodic or chronic migraine: SF-36 analysis across the spectrum of migraine","volume":"22","author":"Diamond M","year":"2019","unstructured":"Diamond M, Lipton R, Horblyuk R, Hirman J, Cady R, Kassel E. Impact of eptinezumab on the health-related quality of life (HRQoL) of patients with episodic or chronic migraine: SF-36 analysis across the spectrum of migraine. Value Health. 2019, 22:S285.","journal-title":"Value Health"},{"key":"ref24","article-title":"Migraine-free months in patients with episodic or chronic migraine treated with eptinezumab: results from the PROMISE-1 and PROMISE-2 trials","volume":"59","author":"Winner PK","year":"2019","unstructured":"Winner PK, McAllister P, Cady R, Snapinn S, Hirman J, Kassel E. Migraine-free months in patients with episodic or chronic migraine treated with eptinezumab: results from the PROMISE-1 and PROMISE-2 trials. Headache. 2019, 59:162.","journal-title":"Headache"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1111\/head.14036","article-title":"Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache: subgroup analysis of PROMISE-2","volume":"61","author":"Diener HC","year":"2021","unstructured":"Diener HC, Marmura MJ, Tepper SJ, et al.. Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache: subgroup analysis of PROMISE-2. Headache. 2021, 61:125-36. 10.1111\/head.14036","journal-title":"Headache"},{"key":"ref26","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.92.15_supplement.P1.10-023","article-title":"Eptinezumab reduces migraine frequency within the first month after treatment in patients with episodic or chronic migraine","volume":"92","author":"Winner P","year":"2019","unstructured":"Winner P, McAllister P, Kassel E, et al.. Eptinezumab reduces migraine frequency within the first month after treatment in patients with episodic or chronic migraine. Neurology. 2019, 92:20.","journal-title":"Neurology"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1111\/head.14007","article-title":"Eptinezumab demonstrated efficacy in sustained prevention of episodic and chronic migraine beginning on day 1 after dosing","volume":"60","author":"Dodick DW","year":"2020","unstructured":"Dodick DW, Gottschalk C, Cady R, Hirman J, Smith J, Snapinn S. Eptinezumab demonstrated efficacy in sustained prevention of episodic and chronic migraine beginning on day 1 after dosing. Headache. 2020, 60:2220-31. 10.1111\/head.14007","journal-title":"Headache"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/head.13549","article-title":"61st annual scientific meeting American Headache Society","volume":"59 Suppl 1","year":"2019","unstructured":"61st annual scientific meeting American Headache Society. Headache. 2019, 59 Suppl 1.1-208. 10.1111\/head.13549","journal-title":"Headache"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-021-02123-w","article-title":"Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial","volume":"21","author":"Kudrow D","year":"2021","unstructured":"Kudrow D, Cady RK, Allan B, Pederson SM, Hirman J, Mehta LR, Schaeffler BA. Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial. BMC Neurol. 2021, 21:126. 10.1186\/s12883-021-02123-w","journal-title":"BMC Neurol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.7665","article-title":"Effects of intravenous eptinezumab vs placebo on headache pain and most bothersome symptom when initiated during a migraine attack: a randomized clinical trial","volume":"325","author":"Winner PK","year":"2021","unstructured":"Winner PK, McAllister P, Chakhava G, et al.. Effects of intravenous eptinezumab vs placebo on headache pain and most bothersome symptom when initiated during a migraine attack: a randomized clinical trial. JAMA. 2021, 325:2348-56. 10.1001\/jama.2021.7665","journal-title":"JAMA"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1002\/edm2.217","article-title":"Tolerability of eptinezumab in overweight, obese or type 1 diabetes patients","volume":"4","author":"Baker B","year":"2021","unstructured":"Baker B, Schaeffler B, Hirman J, Hompesch M, Pederson S, Smith J. Tolerability of eptinezumab in overweight, obese or type 1 diabetes patients. Endocrinol Diabetes Metab. 2021, 4:e00217. 10.1002\/edm2.217","journal-title":"Endocrinol Diabetes Metab"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-021-01227-5","article-title":"Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials","volume":"22","author":"Smith TR","year":"2021","unstructured":"Smith TR, Spierings EL, Cady R, et al.. Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials. J Headache Pain. 2021, 22:16. 10.1186\/s10194-021-01227-5","journal-title":"J Headache Pain"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1177\/0333102420912726","article-title":"Long-term safety and efficacy of erenumab in patients with chronic migraine: results from a 52-week, open-label extension study","volume":"40","author":"Tepper SJ","year":"2020","unstructured":"Tepper SJ, Ashina M, Reuter U, et al.. Long-term safety and efficacy of erenumab in patients with chronic migraine: results from a 52-week, open-label extension study. Cephalalgia. 2020, 40:543-53. 10.1177\/0333102420912726","journal-title":"Cephalalgia"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000010600","article-title":"Long-term safety, tolerability, and efficacy of fremanezumab in migraine: a randomized study","volume":"95","author":"Goadsby PJ","year":"2020","unstructured":"Goadsby PJ, Silberstein SD, Yeung PP, Cohen JM, Ning X, Yang R, Dodick DW. Long-term safety, tolerability, and efficacy of fremanezumab in migraine: a randomized study. Neurology. 2020, 95:e2487-99. 10.1212\/WNL.0000000000010600","journal-title":"Neurology"},{"key":"ref35","unstructured":"A study in children and young people with migraine to learn what the body does to eptinezumab. (2020). Accessed. August 28, 2021: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04537429."},{"key":"ref36","unstructured":"A study with eptinezumab in adolescents (12-17 Years) with chronic migraine (PROSPECT-2). (2021). Accessed. August 28, 2021: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04965675."},{"key":"ref37","unstructured":"Eptinezumab in healthy japanese subjects. (2020). Accessed. August 28, 2021: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04336449."},{"key":"ref38","unstructured":"Vyepti prices, coupons & savings tips - GoodRx. (2021). Accessed. August 28, 2021: https:\/\/www.goodrx.com\/vyepti."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/70762-a-review-of-eptinezumab-use-in-migraine","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,8]],"date-time":"2024-09-08T13:55:09Z","timestamp":1725803709000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/70762-a-review-of-eptinezumab-use-in-migraine"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,16]]},"references-count":38,"URL":"https:\/\/doi.org\/10.7759\/cureus.18032","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9,16]]}}}